Research Topics
Genomes and Genes
| colorectal neoplasmsSummarySummary: Tumors or cancer of the COLON or the RECTUM or both. Risk factors for colorectal cancer include chronic ULCERATIVE COLITIS; FAMILIAL POLYPOSIS COLI; exposure to ASBESTOS; and irradiation of the CERVIX UTERI. Top Publications
Research Grants
| Scientific Experts
|
Detail Information
Publications
Patient preference and pharmacokinetics of oral modulated UFT versus intravenous fluorouracil and leucovorin: a randomised crossover trial in advanced colorectal cancerM M Borner
Early Clinical Studies Group of The European Organization for Research and Treatment of Cancer, Belgium
Eur J Cancer 38:349-58. 2002..v. 5-FU/LV. Oral UFT/LV compares favourably with i.v. 5-FU/LV in terms of toxicity and patient's preference and leads to prolonged 5-FU exposure, which is comparable to continuous i.v. 5-FU treatment...
Low frequency of bacteremia after an endoscopic resection for large colorectal tumors in spite of extensive submucosal exposureByung Hoon Min
Department of Medicine, Sungkyunkwan University School of Medicine, Samsung Medical Center, Gangnam Gu, Seoul, Korea
Gastrointest Endosc 68:105-10. 2008..However, the incidence of bacteremia after an EMR or ESD for colorectal tumors has not been reported...- KRAS mutation testing for predicting response to anti-EGFR therapy for colorectal carcinoma: proposal for an European quality assurance programJ H J M van Krieken
Department of Pathology, Radboud University Nijmegen Medical Centre, Nijmegen, 6500, HB, The Netherlands
Virchows Arch 453:417-31. 2008..We also present guideline recommendations and a proposal for a European quality assurance program to help ensure accuracy and proficiency in KRAS mutation testing across the European Union... - Impact of baseline sum of longest diameter in target lesions by RECIST on survival of patients with metastatic colorectal cancerNozomu Machida
Division of Gastrointestinal Oncology, Shizuoka Cancer Center, Sunto gun, Shizuoka, Japan
Jpn J Clin Oncol 38:689-94. 2008..The objective of this study was to clarify the prognostic impact of Baseline Sum of Longest Diameter (BSLD) of target lesions by Response Evaluation Criteria in Solid Tumor (RECIST) in patients with mCRC... - Alternating XELFOX and XELFIRI in patients with metastatic colorectal cancerFrancesco Recchia
Ospedale Civile di Avezzano, Unita Operativa di Oncologia, Rome, Italy
Am J Clin Oncol 31:323-8. 2008.... - Cetuximab and chemotherapy as initial treatment for metastatic colorectal cancerEric Van Cutsem
University Hospital Gasthuisberg, Digestive Oncology Unit, Herestraat 49, 3000 Leuven, Belgium
N Engl J Med 360:1408-17. 2009.... - The consensus coding sequences of human breast and colorectal cancersTobias Sjoblom
Ludwig Center and Howard Hughes Medical Institute, Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, MD 21231, USA
Science 314:268-74. 2006..These data define the genetic landscape of two human cancer types, provide new targets for diagnostic and therapeutic intervention, and open fertile avenues for basic research in tumor biology... 
Phenotypic characterization of human colorectal cancer stem cellsPiero Dalerba
Department of Internal Medicine, University of Michigan, Ann Arbor, MI 48109, USA
Proc Natl Acad Sci U S A 104:10158-63. 2007..These results validate the stem cell working model in human CRC and provide a highly robust surface marker profile for CRC stem cell isolation...- Type, density, and location of immune cells within human colorectal tumors predict clinical outcomeJerome Galon
INSERM U 255, Paris, 75006 France Université Paris Descartes Paris 5, Faculte de Medecine, Paris, 75006 France
Science 313:1960-4. 2006..In situ analysis of tumor-infiltrating immune cells may therefore be a valuable prognostic tool in the treatment of colorectal cancer and possibly other malignancies... - Chemotherapy, bevacizumab, and cetuximab in metastatic colorectal cancerJolien Tol
Radboud University Nijmegen Medical Center, Nijmegen, The Netherlands
N Engl J Med 360:563-72. 2009..We studied the effect of adding the anti-epidermal growth factor receptor (EGFR) antibody cetuximab to a combination of capecitabine, oxaliplatin, and bevacizumab for metastatic colorectal cancer... - Effects of KRAS, BRAF, NRAS, and PIK3CA mutations on the efficacy of cetuximab plus chemotherapy in chemotherapy-refractory metastatic colorectal cancer: a retrospective consortium analysisWendy De Roock
Centre for Human Genetics, KU Leuven, Leuven, Belgium
Lancet Oncol 11:753-62. 2010.... - DNA methylation markers in colorectal cancerMyoung Sook Kim
Department of Otolaryngology, Head and Neck Surgery, The Johns Hopkins University School of Medicine, 1550 Orleans Street, CRB II 5M, Baltimore, MD, 21231, USA
Cancer Metastasis Rev 29:181-206. 2010..Therefore, the aim of this review is to understand DNA methylation as a driving force in colorectal neoplasia and its emerging value as a molecular marker in the clinic... - Once-only flexible sigmoidoscopy screening in prevention of colorectal cancer: a multicentre randomised controlled trialWendy S Atkin
Department of Surgery and Cancer, Imperial College London, London, UK
Lancet 375:1624-33. 2010..We tested the hypothesis that only one flexible sigmoidoscopy screening between 55 and 64 years of age can substantially reduce colorectal cancer incidence and mortality... - Colorectal cancerDavid Cunningham
Gastrointestinal Unit, Royal Marsden Hospital National Health Service Foundation Trust, London and Surrey, UK
Lancet 375:1030-47. 2010..However, biomarker development is essential to aid selection of patients likely to respond to therapy, thereby rationalising treatments and improving outcomes... - Effector memory T cells, early metastasis, and survival in colorectal cancerFranck Pages
INSERM UNITE 255, René Descartes Faculté de Médecine, Assistance Publique Hopitaux de Paris, Cordeliers Biomedical Research Center, University Paris 6, Paris, France
N Engl J Med 353:2654-66. 2005..The role of tumor-infiltrating immune cells in the early metastatic invasion of colorectal cancer is unknown... - Analysis of PTEN, BRAF, and EGFR status in determining benefit from cetuximab therapy in wild-type KRAS metastatic colon cancerPierre Laurent-Puig
INSERM UMR S775 Molecular Basis of Xenobiotics Response, Paris, France
J Clin Oncol 27:5924-30. 2009..However, only half of these patients will benefit from treatment, suggesting the need to identify additional biomarkers for cetuximab-based treatment efficacy... - American College of Gastroenterology guidelines for colorectal cancer screening 2009 [corrected]Douglas K Rex
Indiana University Medical Center, IU Hospital, Indianapolis 46202, USA
Am J Gastroenterol 104:739-50. 2009.... - Screening for colorectal cancer: U.S. Preventive Services Task Force recommendation statementNed Calonge
Ann Intern Med 149:627-37. 2008..D recommendation). The USPSTF concludes that the evidence is insufficient to assess the benefits and harms of computed tomographic colonography and fecal DNA testing as screening modalities for colorectal cancer. (I statement)... - Classification of colorectal cancer based on correlation of clinical, morphological and molecular featuresJ R Jass
Department of Pathology, McGill University, Montreal, Canada
Histopathology 50:113-30. 2007..This approach to the classification of CRC should accelerate understanding of causation and will impact on clinical management in the areas of both prevention and treatment... - Randomized, phase III trial of panitumumab with infusional fluorouracil, leucovorin, and oxaliplatin (FOLFOX4) versus FOLFOX4 alone as first-line treatment in patients with previously untreated metastatic colorectal cancer: the PRIME studyJean Yves Douillard
Centre Rene Gauducheau, Nantes, France
J Clin Oncol 28:4697-705. 2010.... - Randomized phase III study of panitumumab with fluorouracil, leucovorin, and irinotecan (FOLFIRI) compared with FOLFIRI alone as second-line treatment in patients with metastatic colorectal cancerMarc Peeters
University Hospital Ghent, Ghent, Belgium
J Clin Oncol 28:4706-13. 2010..This trial evaluated the efficacy and safety of panitumumab plus fluorouracil, leucovorin, and irinotecan (FOLFIRI) compared with FOLFIRI alone after failure of initial treatment for mCRC by tumor KRAS status... - Meta-analysis of genome-wide association data identifies four new susceptibility loci for colorectal cancerRichard S Houlston
Section of Cancer Genetics, Institute of Cancer Research, Sutton, UK
Nat Genet 40:1426-35. 2008..1 (rs10411210, RHPN2; P = 4.6 x 10(-9)) and 20p12.3 (rs961253; P = 2.0 x 10(-10)). These findings underscore the value of large sample series for discovery and follow-up of genetic variants contributing to the etiology of CRC... - Colorectal cancerJurgen Weitz
Department of Surgery, University of Heidelberg, Heidelberg, Germany
Lancet 365:153-65. 2005..Further clinical progress will largely depend on the broader implementation of multidisciplinary treatment strategies following the principles of evidence-based medicine... - Randomized trial of laparoscopic-assisted resection of colorectal carcinoma: 3-year results of the UK MRC CLASICC Trial GroupDavid G Jayne
Academic Unit of Surgery, St James s University Hospital, Leeds, United Kingdom
J Clin Oncol 25:3061-8. 2007..Few data are available on rectal cancer, and long-term data on survival and recurrence are now required... - Folate and colorectal cancer: an evidence-based critical reviewYoung In Kim
Department of Medicine and Nutritional Sciences, Medical Sciences Building, University of Toronto, 1 King s College Circle, Toronto, Ontario, Canada
Mol Nutr Food Res 51:267-92. 2007..inhibitory effect whereas folate supplementation has a promoting effect on the progression of established colorectal neoplasms. In contrast, folate deficiency in normal colorectal mucosa appears to predispose it to neoplastic .. - Microsatellite instability in colorectal cancerC Richard Boland
GI Cancer Research Laboratory, Division of Gastroenterology, Department of Internal Medicine, Sammons Cancer Center and Baylor Research Institute, Baylor University Medical Center, Dallas, Texas, USA
Gastroenterology 138:2073-2087.e3. 2010..Discovery of MSI in colorectal tumors has increased awareness of the diversity of colorectal cancers and implications for specialized management of patients... - High frequency of mutations of the PIK3CA gene in human cancersYardena Samuels
Sidney Kimmel Comprehensive Cancer Center, Howard Hughes Medical Institute, The Johns Hopkins University Medical Institutions, Baltimore, MD 21231, USA
Science 304:554. 2004 - Systemic treatment of colorectal cancerBrian M Wolpin
Department of Medicine, Harvard Medical School, Boston, Massachusetts, USA
Gastroenterology 134:1296-310. 2008.... - Dietary fiber and colorectal cancer risk: a nested case-control study using food diariesChristina C Dahm
Department of Public Health and Primary Care, University of Cambridge, Cambridge CB1 8RN, UK
J Natl Cancer Inst 102:614-26. 2010..Results of epidemiological studies of dietary fiber and colorectal cancer risk have not been consistent, possibly because of attenuation of associations due to measurement error in dietary exposure ascertainment... - Identification of key genes for carcinogenic pathways associated with colorectal adenoma-to-carcinoma progressionAnke H Sillars-Hardebol
Department of Pathology Tumor Profiling Unit, VU University Medical Center, De Boelelaan 1117, 1081HV, Amsterdam, The Netherlands
Tumour Biol 31:89-96. 2010.... - Critical evaluation of current treatments in metastatic colorectal cancerAlan Venook
Division of Medical Oncology, Clinical Research Office, University of California Cancer Center, Box 1705, 1600 Divisadero, San Francisco, California 94115 1705, USA
Oncologist 10:250-61. 2005..This review discusses the role of the individual agents in the treatment of mCRC and identifies the most effective regimens... - Epigenetic silencing of microRNA-34b/c and B-cell translocation gene 4 is associated with CpG island methylation in colorectal cancerMinoru Toyota
First Department of Internal Medicine, Cancer Research Institute, Sapporo Medical University, Sapporo, Japan
Cancer Res 68:4123-32. 2008..Our results suggest that miR-34b/c and BTG4 are novel tumor suppressors in CRC and that the miR-34b/c CpG island, which bidirectionally regulates miR-34b/c and BTG4, is a frequent target of epigenetic silencing in CRC... - CpG island methylator phenotype underlies sporadic microsatellite instability and is tightly associated with BRAF mutation in colorectal cancerDaniel J Weisenberger
Department of Surgery, University of Southern California Norris Comprehensive Cancer Center, Los Angeles, California 90089 9176, USA
Nat Genet 38:787-93. 2006..Sporadic cases of mismatch repair deficiency occur almost exclusively as a consequence of CIMP-associated methylation of MLH1 . We propose a robust new marker panel to classify CIMP+ tumors... - A genome-wide association study identifies colorectal cancer susceptibility loci on chromosomes 10p14 and 8q23.3Ian P M Tomlinson
Molecular and Population Genetics Laboratory, London Research Institute, Cancer Research UK, London WC2A 3PX, UK
Nat Genet 40:623-30. 2008..3 (P = 3.3 x 10(-18) overall; P = 9.6 x 10(-17) replication), which tags a plausible causative gene, EIF3H. These data provide further evidence for the 'common-disease common-variant' model of CRC predisposition... - Chemotherapy for colorectal cancer in the metastatic and adjuvant setting: past, present and futureAmi Sabharwal
Cancer Research UK, Medical Oncology Unit, Churchill Hospital, Oxford, UK
Expert Rev Anticancer Ther 7:477-87. 2007..The evolution of chemotherapy use, current practice in the metastatic and adjuvant setting and possible future directions are discussed... - Jagged1 is the pathological link between Wnt and Notch pathways in colorectal cancerVeronica Rodilla
Institut d Investigació Biomèdica de Bellvitge Gran Via km 2 7, Hospitalet and Institut Municipal d Investigacions Mèdiques Hospital del Mar, Dr Aiguader 88, 08003 Barcelona, Spain
Proc Natl Acad Sci U S A 106:6315-20. 2009..The Notch-specific genetic signature is sufficient to block differentiation and promote vasculogenesis in tumors whereas proliferation depends on both pathways... - Trends in colorectal cancer test use in the medicare population, 1998-2005Anna P Schenck
The Carolinas Center for Medical Excellence, Cary, North Carolina 27518 8598, USA
Am J Prev Med 37:1-7. 2009..Colorectal cancer (CRC) screening has been covered under the Medicare program since 1998. No prior study has addressed the question of the completeness of CRC screening in the entire Medicare cohort... - The advanced adenoma as the primary target of screeningSidney J Winawer
Department of Medicine, Memorial Sloan Kettering Cancer Center, and Weill Medical College of Cornell University, New York, New York 10021, USA
Gastrointest Endosc Clin N Am 12:1-9, v. 2002.... - Treatment in advanced colorectal cancer: what, when and how?I Chau
Department of Medicine, Royal Marsden Hospital, Sutton, Surrey, UK
Br J Cancer 100:1704-19. 2009..In this review, we have focused on the implications of these trial results on the everyday management decisions of treating advanced CRC... - Patient and physician reminders to promote colorectal cancer screening: a randomized controlled trialThomas D Sequist
Department of Health Care Policy, Harvard Medical School, 180 Longwood Avenue, Boston, MA 02115, USA
Arch Intern Med 169:364-71. 2009..Screening reduces colorectal cancer mortality, but effective screening tests remain underused. Systematic reminders to patients and physicians could increase screening rates.. - [Update S3-guideline "colorectal cancer" 2008]W Schmiegel
Verantwortliche Institution (Leitliniensekretariat): Medizinische Klinik, Knappschaftskrankenhaus,
Z Gastroenterol 46:799-840. 2008 - Association between exposure-relevant polymorphisms in CYP1B1, EPHX1, NQO1, GSTM1, GSTP1 and GSTT1 and risk of colorectal cancer in a Czech populationIvona Hlavata
Toxicogenomics Unit, National Institute of Public Health, 100 42 Prague, Czech Republic
Oncol Rep 24:1347-53. 2010..These results provide further evidence that interaction between metabolic gene variants contributes to colorectal carcinogenesis... - Diabetes mellitus and risk of colorectal cancer: a meta-analysisSusanna C Larsson
Division of Nutritional Epidemiology, The National Institute of Environmental Medicine, Karolinska Institutet, Stockholm, Sweden
J Natl Cancer Inst 97:1679-87. 2005..To resolve these inconsistencies, we conducted a meta-analysis of published data on the association between diabetes and the incidence and mortality of colorectal cancer... - Quick-multiplex-consensus (QMC)-PCR followed by high-resolution melting: a simple and robust method for mutation detection in formalin-fixed paraffin-embedded tissueWakkas Fadhil
Division of Pathology, School of Molecular Medical Sciences, University of Nottingham, Nottingham, UK
J Clin Pathol 63:134-40. 2010..Mutation detection in tumours will become increasingly important in pathological diagnosis as 'predictive' mutations are identified. A cheap and reliable test that works on formalin-fixed paraffin-embedded (FFPE) tissue is required... - Prognostic significance of CDKN2A (p16) promoter methylation and loss of expression in 902 colorectal cancers: Cohort study and literature reviewKaori Shima
Department of Medical Oncology, Dana Farber Cancer Institute and Harvard Medical School, Boston, Massachusetts, USA
Int J Cancer 128:1080-94. 2011..Despite its well-established role in carcinogenesis, CDKN2A (p16) promoter methylation or loss of expression in colorectal cancer is not independently associated with patient prognosis... - Association of KRAS p.G13D mutation with outcome in patients with chemotherapy-refractory metastatic colorectal cancer treated with cetuximabWendy De Roock
Center for Human Genetics, University of Leuven, Leuven, Belgium
JAMA 304:1812-20. 2010..Patients with metastatic colorectal cancer who have KRAS codon 12- or KRAS codon 13-mutated tumors are presently excluded from treatment with the anti-epidermal growth factor receptor monoclonal antibody cetuximab... - Trop2 expression contributes to tumor pathogenesis by activating the ERK MAPK pathwayRafael Cubas
Department of Molecular Virology and Microbiology, Baylor College of Medicine, Houston, TX 77030, USA
Mol Cancer 9:253. 2010..Here, we studied the effects murine Trop2 (mTrop2) exerted on tumor cellular functions and some of the signaling mechanisms activated by this oncogene... - Risk factors for an adverse outcome in early invasive colorectal carcinomaHideki Ueno
Department of Surgery I, National Defense Medical College, Saitama, Japan
Gastroenterology 127:385-94. 2004..Various histologic findings exist for managing patients with malignant polyps. Our goal was to determine the criteria for a conservative approach to patients with locally excised early invasive carcinoma... - Comprehensive profiling of DNA methylation in colorectal cancer reveals subgroups with distinct clinicopathological and molecular featuresPei Woon Ang
Cancer Science Institute of Singapore, National University of Singapore, Singapore, Singapore
BMC Cancer 10:227. 2010..In the present study we performed comprehensive DNA methylation profiling of CRC with the aim of characterizing CIMP subgroups... - The stem cell marker CD133 associates with enhanced colony formation and cell motility in colorectal cancerTarek M A Elsaba
Division of Pathology, School of Molecular Medical Sciences, Queen s Medical Centre, University of Nottingham, Nottingham, United Kingdom
PLoS ONE 5:e10714. 2010..We conclude that CD133 expression in CRCs is associated with some features attributable to stemness and that there is plasticity of CD133 expression. Further studies are necessary to delineate the mechanistic basis of these features... - Molecular characterization of mucosal adherent bacteria and associations with colorectal adenomasXiang Jun Shen
Center for Gastrointestinal Biology and Disease University of North Carolina at Chapel Hill, NC, USA
Gut Microbes 1:138-47. 2010..Extension of these findings could lead to strategies to manipulate the microbiota to prevent colorectal adenomas and cancer as well as to identify individuals at high risk... - Evidence for colorectal cancer screeningMichael Bretthauer
Centre for Colorectal Cancer Screening, The Cancer Registry of Norway, Oslo University Hospital, PO Box 5313 Majorstuen, N 0304 Oslo, Norway
Best Pract Res Clin Gastroenterol 24:417-25. 2010..FOBT and flexible sigmoidoscopy are the two CRC screening methods which have been tested in randomised trials and shown to reduce CRC mortality. These tests can be recommended for CRC screening... - Colorectal cancer: national and international perspective on the burden of disease and public health impactZiad F Gellad
Durham VA Medical Center and Department of Medicine, Division of Gastroenterology, Duke University Medical Center, Durham, North Carolina, USA
Gastroenterology 138:2177-90. 2010..Despite the strong impact of colorectal cancer on public health, there is cause for optimism and room for hope... - Novel application of structural equation modeling to correlation structure analysis of CpG island methylation in colorectal cancerNoriko Tanaka
Department of Biostatistics, Harvard School of Public Health, Boston, MA, USA
Am J Pathol 177:2731-40. 2010..Our novel data suggest two distinct perturbations, resulting in differential locus-specific propensity of CpG methylation... - The HER-2/neu oncogene in tumors of the gastrointestinal tractJ S Ross
Department of Pathology and Laboratory Medicine MC 81, Albany Medical College, 47 New Scotland Ave, Albany, NY 12208, USA
Cancer Invest 19:554-68. 2001.... - Different occurrence of CD8+, CD45R0+, and CD68+ immune cells in regional lymph node metastases from colorectal cancer as potential prognostic predictorsA Oberg
Department of Surgical and Perioperative Sciences, Umea University Hospital, Sweden
Int J Colorectal Dis 17:25-9. 2002..To study whether there are differences in the immunohistochemical staining of CD8, CD45R0, and CD68 of immune cells in regional lymph node metastases from colorectal cancer that are of potential interest in prognostic prediction... - Distinct genetic alterations in colorectal cancerHassan Ashktorab
Department of Medicine and Cancer Center, Howard University, College of Medicine, Washington, DC, United States of America
PLoS ONE 5:e8879. 2010..In this study, we determined genomic copy number aberrations in sporadic CRC tumors from AAs, in order to investigate possible explanations for the observed disparities... - Role of miR-143 targeting KRAS in colorectal tumorigenesisX Chen
Jiangsu Diabetes Center, State Key Laboratory of Pharmaceutical Biotechnology, School of Life Sciences, Nanjing University, Nanjing, Jiangsu, China
Oncogene 28:1385-92. 2009..Taken together, the present study provides the first evidences that miR-143 is significant in suppressing colorectal cancer cell growth through inhibition of KRAS translation... - Development of a multiplex MethyLight assay for the detection of multigene methylation in human colorectal cancerQiong He
Department of Human Anatomy and Neurobiology, Sun Yat Sen University, Guangzhou, Guangdong, P R China
Cancer Genet Cytogenet 202:1-10. 2010.... - Two groups of DNA methylation markers to classify colorectal cancer into three epigenotypesAtsushi Kaneda
Genome Science Division, Research Center for Advanced Science and Technology, University of Tokyo, Meguro ku, Tokyo
Cancer Sci 102:18-24. 2011..Here we review and compare our recent study and reported CRC classification methods by DNA methylation information, and propose the use of two panels of methylation markers as CRC classifiers... - Decreased levels of plasma adiponectin associated with increased risk of colorectal cancerSayaka Otake
Division of Endoscopy, Yamagata University Hospital, 2 2 2 Iida nishi, Yamagata 990 9585, Japan
World J Gastroenterol 16:1252-7. 2010..To investigate the association between adiponectin levels and risk of colorectal adenoma and cancer (early and advanced)... - Atonal homolog 1 is required for growth and differentiation effects of notch/gamma-secretase inhibitors on normal and cancerous intestinal epithelial cellsAvedis Kazanjian
Division of Gastroenterology, Hepatology, and Nutrition, Cincinnati Children s Hospital Medical Center, Cincinnati, Ohio, USA
Gastroenterology 139:918-28, 928.e1-6. 2010..We used genetic analyses of mice to determine whether Atoh1 mediates the effects of GSIs in normal and cancerous intestinal epithelia... - Polymorphisms in methyl-group metabolism genes and risk of sporadic colorectal cancer with relation to the CpG island methylator phenotypePawel Karpinski
Department of Genetics, Wroclaw Medical University, ul Marcinkowskiego 1, Wroclaw, Poland
Cancer Epidemiol 34:338-44. 2010..The aim of the present study was to evaluate whether polymorphisms in the genes encoding methyl-group metabolism pathway predispose to CIMP+ and/or CIMP- CRC... - Caught up in a Wnt storm: Wnt signaling in cancerRachel H Giles
Hubrecht Laboratory, Netherlands Institute for Developmental Biology, Uppsalalaan 8, 3584 CT, Utrecht, The Netherlands
Biochim Biophys Acta 1653:1-24. 2003.... - Individualized therapies in colorectal cancer: KRAS as a marker for response to EGFR-targeted therapyDavid Z Chang
Departments of Gastrointestinal Medical Oncology, The University of Texas, MD Anderson Cancer Center, Houston, Texas, USA
J Hematol Oncol 2:18. 2009..It should now become a standard practice that any patients being considered for EGFR targeted therapies have their tumors tested for KRAS status and only those with wild-type KRAS being offered such therapies... - Prognostic factors and analysis of microsatellite instability in resected pulmonary metastases from colorectal carcinomaGiulio Melloni
Department of Thoracic Surgery, Scientific Institute H San Raffaele, Milan, Italy
Ann Thorac Surg 81:2008-13. 2006..The aims were to search for factors influencing prognosis and to investigate the presence of microsatellite instability in the primary tumors and the corresponding lung metastases... - Phase II trial of capecitabine and oxaliplatin (CAPOX) plus cetuximab in patients with metastatic colorectal cancer who progressed after oxaliplatin-based chemotherapyJ Souglakos
Department of Medical Oncology, University General Hospital of Heraklion, Heraklion, Crete, Greece
Ann Oncol 18:305-10. 2007..Thirty-one (77.5%) and nine (22.5%) patients had oxaliplatin-refractory and -resistant disease, respectively; in addition, 32 (80%) patients had also progressed on prior irinotecan-based chemotherapy... - Nup88 expression in normal mucosa, adenoma, primary adenocarcinoma and lymph node metastasis in the colorectumZhi Yong Zhang
Department of Pathology, Tangshan Worker s Hospital, Tangshan, China
Tumour Biol 28:93-9. 2007..It was the aim of this study to investigate Nup88 expression in normal colorectal mucosa, adenoma, adenocarcinoma and lymph node metastasis, as well as the relationship between Nup88 expression and clinicopathological features... - Clinicopathologic and immunohistochemical study of small apparently "de novo" colorectal adenocarcinomasJason L Hornick
Department of Pathology, Brigham and Women s Hospital, Harvard Medical School, Boston, MA 02115, USA
Am J Surg Pathol 31:207-15. 2007.... - Quantitative estimation of CEA and CK20 expression in tumour tissue of colorectal cancer and its liver metastases with reverse transcription and real-time PCRMonika Cerna
Second Clinic of Internal Medicine, Faculty Hospital Pilsen, Czech Republic
Anticancer Res 26:803-8. 2006..CONCLUSION: The measurement of CEA and CK20 gene expressions in tumours did not supply any new prognostic information, but raised the question of the mechanism releasing CEA into the blood... - MYH, OGG1, MTH1, and APC alterations involved in the colorectal tumorigenesis of Korean patients with multiple adenomasJin C Kim
Department of Surgery, University of Ulsan College of Medicine, Seoul, South Korea
Virchows Arch 450:311-9. 2007..Some BER variants involved in specific APC mutations are associated with characteristics of histogenesis other than altered mismatch repair or p53 pathway... - Long-term characteristics of 5-year survivors after liver resection for colorectal metastasesKuniya Tanaka
Department of Gastroenterological Surgery, Yokohama City University Graduate School of Medicine, 3 9 Fukuura, Kanazawa Ku, Yokohama 236 0004, Japan
Ann Surg Oncol 14:1336-46. 2007..Although retrospective studies have demonstrated survival benefit of hepatectomy for metastatic colorectal cancer, few have included sufficient 5-year survivors to identify survival-related factors throughout the clinical course... - FDG-PET in colorectal cancerLioe Fee de Geus-Oei
Department of Nuclear Medicine, Radboud University, Nijmegen Medical Centre, Nijmegen, The Netherlands
Cancer Imaging 6:S71-81. 2006..This review aims to outline the current and future role of FDG-PET in the field of colorectal cancer... - Significance of tenascin-C, fibronectin, laminin, collagen IV, alpha5beta1 and alpha9beta1 integrins and fibrotic capsule formation around liver metastases originating from cancers of the digestive tractM V Gulubova
Department of General and Clinical Pathology, Medical Faculty, Trakia University, 6000 Stara Zagora, Bulgaria
Neoplasma 53:372-83. 2006..The results indicate that fibrotic capsule formation is associated with longer survival after surgery. The appearance of tenascin-C and of its receptor at the periphery of liver metastases could be used as a sign of invasiveness... - Importance of histological tumor response assessment in predicting the outcome in patients with colorectal liver metastases treated with neo-adjuvant chemotherapy followed by liver surgeryL Rubbia Brandt
Unit of Gastrointestinal and Liver Pathology, University Hospital, Geneva, Switzerland
Ann Oncol 18:299-304. 2007.... - Downregulated P1 promoter-driven hepatocyte nuclear factor-4alpha expression in human colorectal carcinoma is a new prognostic factor against liver metastasisTomoko Oshima
Divisions of Cellular and Molecular Pathology, Niigata University Graduate School of Medical and Dental Sciences, Niigata, Japan
Pathol Int 57:82-90. 2007..These findings suggest that downregulation of P1 expression is involved in tumor metastasis and a worse prognosis... - Appraisal of 1 cm hepatectomy margins for intrahepatic micrometastases in patients with colorectal carcinoma liver metastasisToshifumi Wakai
Division of Digestive and General Surgery, Niigata University Graduate School of Medical and Dental Sciences, 1 757 Asahimachi dori, Chuo Ku, Niigata City, 951 8510, Japan
Ann Surg Oncol 15:2472-81. 2008..This study sought to clarify the distribution of intrahepatic micrometastases and elucidate an adequate hepatectomy margin for colorectal carcinoma liver metastases... - Clinicopathological analysis of colorectal cancer liver metastasis and intrahepatic cholangiocarcinoma: are they just apples and oranges?C T Chiu
Department of Gastroenterology, Chang Gung Memorial Hospital, Chang Gung University, Taipei, Taiwan
Dig Liver Dis 40:749-54. 2008..Intrahepatic cholangiocarcinoma and colorectal cancer liver metastasis are the most primary and secondary adenocarcinoma of the liver, respectively. A large-scale long-term comparative study of these two cohort patient is lacking... - Clinical significance of BMP7 in human colorectal cancerKazuo Motoyama
Department of Molecular and Surgical Oncology, Medical Institute of Bioregulation, Kyushu University, 4546 Tsurumibaru, Beppu, 874 0838, Japan
Ann Surg Oncol 15:1530-7. 2008.... - [Effectiveness of screening colonoscopy in a community-based study]D Hüppe
Gastroenterologische Gemeinschaftspraxis Herne, Herne
Z Gastroenterol 46:193-200. 2008..Screening colonoscopy detects colorectal cancers in the early stages. Given the favourable prognosis in these stages, screening can reduce CRC-related mortality... - Peritumoural, but not intratumoural, lymphatic vessel density and invasion correlate with colorectal carcinoma poor-outcome markersAdhemar Longatto-Filho
Life and Health Sciences Research Institute, University of Minho, 4710 057, Braga, Portugal
Virchows Arch 452:133-8. 2008..016), nodal metastasis (p = 0.022) and hepatic metastasis (p < 0.001). Peritumoural LVD and LVI are directly related to histopathological variables indicative of poor outcome such as lymph-node status and liver metastasis... - Chemotherapy-induced suppression to adenoma or complete suppression of the primary in patients with stage IV colorectal cancer: report of four casesThomas Armbrust
Department of Gastroenterology and Endocrinology, Georg August University, Gottingen, Germany
Eur J Gastroenterol Hepatol 19:988-94. 2007.... - Increased expression of thioredoxin-1, vascular endothelial growth factor, and redox factor-1 is associated with poor prognosis in patients with liver metastasis from colorectal cancerTerumasa Noike
Department of Surgery, Shinshu University School of Medicine, Matsumoto 3908621, Japan
Hum Pathol 39:201-8. 2008..Expression of VEGF and Ref-1 is associated with Trx-1 overexpression, which is related to a poor prognosis in patients with liver metastases from colorectal cancer... - Improved long-term outcome of surgery for advanced colorectal liver metastases: reasons and implications for management on the basis of a severity scoreAxel Andres
Unit of Visceral and Transplantation Surgery, University Hospitals of Geneva, 1211, Geneva 14, Switzerland
Ann Surg Oncol 15:134-43. 2008..To quantify this assumption and to understand its causes we analyzed a series of patients on the basis of a standardized severity score and changes in management occurring over the years... - Reduced expression of Apaf-1 in colorectal adenocarcinoma correlates with tumor progression and aggressive phenotypeSeung Sam Paik
Department of Pathology, College of Medicine, Hanyang University, Seoul, Korea
Ann Surg Oncol 14:3453-9. 2007.... - Clinical outcomes of FOLFOX/FOLFIRI for the Japanese patients with far-advanced or recurrent colorectal cancerHiroshi Saeki
Department of Surgery, Nippon Steel Yawata Memorial Hospital, 1 1 1 Harunomachi, Yahatahigashi ku, Kitakyushu, 805 8508, Japan
Fukuoka Igaku Zasshi 98:253-9. 2007..Oxaliplatin, Irinotecan, 5-fluorouracil and leucovorin are commonly used to treat advanced colorectal cancer in Western countries. Here, we investigated the efficacy and safety of FOLFOX/FOLFIRI in Japanese colorectal cancer patients... - Bevacizumab in combination with oxaliplatin, fluorouracil, and leucovorin (FOLFOX4) for previously treated metastatic colorectal cancer: results from the Eastern Cooperative Oncology Group Study E3200Bruce J Giantonio
University of Pennsylvania, Philadelphia, PA, USA
J Clin Oncol 25:1539-44. 2007..This study was conducted to determine the effect of bevacizumab (at 10 mg/kg) on survival duration for oxaliplatin-based chemotherapy in patients with previously treated metastatic colorectal cancer... - [Clinical administration of FOLFOX regimens for patients with unresectable advanced or recurrent colorectal cancer]Kazuhito Minami
Dept of Surgery, Saiseikai Hiroshima Hospital
Gan To Kagaku Ryoho 34:573-7. 2007..No patient had grade 3 neurologic toxicity,because no one was administered over 10 cycles. FOLFOX regimens showed good anti-tumor effects but poor tolerability after 5-6 cycles in our patients... - Oxaliplatin, 5-fluorouracil/leucovorin and epirubicin as first-line treatment in advanced gastric carcinoma: a phase II studyB Neri
Department of Oncology, Centre of Experimental and Clinical Oncology, University of Florence, Florence, Italy
Br J Cancer 96:1043-6. 2007..No life threatening or cardiac toxicity was recorded. The regimen used showed anticancer activity against gastric carcinoma, a tolerable toxicity profile and excellent patient compliance... - Cost-effectiveness analysis of first-line chemotherapies in metastatic colorectal cancer. Results of the Fédération Francophone de Cancérologie Digestive (FFCD) 9601 randomized trialIsabelle Borget
Gustave Roussy Institute, Villejuif, France
Oncology 71:40-8. 2006..LD-LV5FU2 appeared a good alternative regimen because it reduced costs without jeopardizing its efficacy. The WI-FU regimen did not show a significant difference in terms of efficacy, but suggested toxicity to be slightly increased... - The prevalence rate and anatomic location of colorectal adenoma and cancer detected by colonoscopy in average-risk individuals aged 40-80 yearsHana Strul
Department of Gastroenterology, Tel-Aviv Sourasky Medical Center, Tel-Aviv, Israel
Am J Gastroenterol 101:255-62. 2006..The significantly high rate of advanced and proximal neoplasia in the elderly, encourages the inclusion of healthy subjects aged 76-80 yr in future prospective studies... - Addition of either irinotecan or methotrexate to bolus 5-fluorouracil and high-dose folinic acid every 2 weeks in advanced colorectal carcinoma: a randomised study by the Southern Italy Cooperative Oncology GroupP Comella
Division of Medical Oncology A, National Tumour Institute, Naples, Italy
Ann Oncol 13:866-73. 2002..v. bolus with a regimen of double modulation of 5-FU with methotrexate (MTX) and FA in patients with advanced colorectal carcinoma... - The potential role of TGFbeta1, TGFbeta2 and TGFbeta3 protein expression in colorectal carcinomas. Correlation with classic histopathologic factors and patient survivalAthanassios C Tsamandas
Department of Pathology, University of Patras School of Medicine, Patras, Greece
Strahlenther Onkol 180:201-8. 2004..TGFbeta1 is related with an increased disease-free and overall survival and constitutes an independent prognostic factor. In advanced stages, TGFbeta2 seems to be involved in tumor progression and is related with worse prognosis... - [Colorectal cancer management]Philippe Rougier
Hépato gastro entérologie, oncologie digestive, Hopital Ambroise Pare, 92104 Boulogne
Rev Prat 54:177-83. 2004..Because of the efficacy of the new chemotherapy regimens, the availability of biotherapies and the fact that surgery can potentially cure more and more patients, colorectal cancer management needs to be multidisciplinary... - Major hepatic resection reduces the probability of intrahepatic recurrences following resection of colorectal carcinoma liver metastasesShigenori Nagakura
Division of Digestive and General Surgery, Niigata University Graduate School of Medical and Dental Sciences, 1-757 Asahimachi-dori, Niigata City, 951-8510 Japan
Hepatogastroenterology 50:779-83. 2003..CONCLUSIONS: Major hepatic resection is more effective in reducing the risk of intrahepatic recurrences than limited hepatic resection in patients with resectable colorectal carcinoma liver metastases... - Recurrence and outcomes following hepatic resection, radiofrequency ablation, and combined resection/ablation for colorectal liver metastasesEddie K Abdalla
Department of Surgical Oncology, University of Texas M. D. Anderson Cancer Center, Houston, TX, USA
Ann Surg 239:818-25; discussion 825-7. 2004..RFA alone or in combination with resection for unresectable patients does not provide survival comparable to resection, and provides survival only slightly superior to nonsurgical treatment... - Benefits of surgery for patients with pulmonary metastases from colorectal carcinomaMasayoshi Inoue
Department of Surgery, Toneyama National Hospital, Toneyama 5 1 1, Toyonaka 560 8552, Osaka, Japan
Ann Thorac Surg 78:238-44. 2004..The aim of this study is to define the patients who benefit from pulmonary metastasectomy for colorectal carcinoma... - [Liver resection after downstaging with neoadjuvant chemotherapy for "unresectable" colorectal metastases]Antonio Frena
Chirurgia Generale 2, Ospedale Regionale, Bolzano
Chir Ital 56:351-7. 2004..This advance can dramatically improve the prognosis of patients with multiple or unresectable liver metastases from colorectal cancer... - Influence of thymidylate synthase and p53 protein expression on clinical outcome in patients with colorectal cancerR Broll
Surgical Research Laboratory, University Clinic of Schleswig Holstein, Campus Lubeck, Ratzeburger Allee 160, 23538 Lubeck, Germany
Int J Colorectal Dis 20:94-102. 2005..For this reason we tested the effect of TS and p53 expression on clinical outcome (tumor recurrence and survival) in patients after curative tumor resection, especially in patients who received adjuvant radio-chemotherapy... - [Evaluation of efficacy and clinical impact of FDG-PET in patients with suspicion of recurrent colorectal cancer]I Borrego Dorado
Unidad de Diagnóstico de Medicina Nuclear, Hospitales Universitarios Virgen del Rocio, Sevilla
Rev Esp Med Nucl 23:313-23. 2004..To evaluate the utility and clinical impact of Positron Emission Tomography with FDG (FDG-PET) in patients with suspected recurrent colorectal cancer (RCR)... - Relationship between matrix metalloproteinase-7 and pit pattern in early stage colorectal cancerYuki Saitoh
Department of Gastroenterology and Hepatology, Yamaguchi University School of Medicine, Ube, Yamaguchi, Japan
Gastrointest Endosc 59:385-92. 2004..CONCLUSIONS: The results of this study indicate that expression of matrix metalloproteinase-7 is related to both the invasiveness of colorectal epithelial tumors and the disturbance of the pit pattern on the tumor surface...
Research Grants
- Nanotechnology Linking Biomarkers with Cancer BehaviorShuming Nie; Fiscal Year: 2007..abstract_text> ..
- DIET, GENETIC SUSCEPTIBILITY AND COLORECTAL ADENOMASLoic Le Marchand; Fiscal Year: 2000..in these foods, is determined by several polymorphic genes; thus, these genes may increase the risk of colorectal neoplasms. The susceptible phenotypes for most of these genes are several times more common in Japanese than ..
- MOLECULAR CLONING OF HLA CLASS II TUMOR ANTIGENSDorothee Herlyn; Fiscal Year: 2003..The antigens also may be of diagnostic value. ..
- Tea Modulation of Colon CarcinogenesisMichael Wargovich; Fiscal Year: 2010..Because RXRa loss involves impairment of regulatory gene networks, the impact of green tea reversal of this transcription factor's loss is significant. ..
- Anti-GM1b IgM for Detection of Localized Prostate CancerMepur Ravindranath; Fiscal Year: 2005....
- ANTIIDIOTYPE VACCINE THERAPY OF HUMAN COLORECTAL CANCERMALAYA CHATTERJEE; Fiscal Year: 2002..These studies will be a prelude to clinical trials for CRC patients with autologous DC based anti-Id vaccine and scFv. ..
- Mechanisms of tumor suppressor gene reactivation in colon cancer by berriesLi Shu Wang; Fiscal Year: 2010..We now propose to evaluate the anthocyanins in berries for their ability to demethylate and reactivate tumor suppressor genes in colon cancer. ..
- IMPROVING VIRTUAL COLONOSCOPY WITH COMPUTER DETECTIONPeter Santago; Fiscal Year: 2001..If VC with CAPD proves accurate and efficient in the diagnosis of colorectal polyps, it could evolve into a simple laboratory test, thereby meeting the demand for worldwide colorectal cancer screening. ..
- The Human Colorectal InstabilitomeStephen Meltzer; Fiscal Year: 2007..c.i To utilize PCA components to find genes segregating with MSI status, and SAM to identify genes significantly differentially expressed among these three groups. ..
- C/EBPbeta Isoform Function & Regulation by Tyrosine KinasesCynthia Zahnow; Fiscal Year: 2009..Functional characterization of the C/EBPB isoforms and the receptor tyrosine kinase pathways that regulate their expression will further our understanding of the molecular basis of mammary development and tumorigenesis. ..
- A Tumor Suppressor Function for the c-Fes Tyrosine Kinase in Colon CancerTHOMAS EDWARD SMITHGALL; Fiscal Year: 2010..If c-fes is a true tumor suppressor, then mice lacking c-fes function are expected to develop more severe disease in terms of tumor size, number, and invasiveness. ..
- Metabolism and Carcinogenicity of Heterocyclic AminesTERRY ZENSER; Fiscal Year: 2007..Determine effect of DSS-induced colitis inflammation) in IQ carcinogenicity. The long-term goal is to understand the role of RNOS on HCA carcinogenesis. ..
- DEVELOPING VIRTUAL COLONOSCOPY FOR CANCER SCREENINGJEROME LIANG; Fiscal Year: 2007....
- Computerized Detection of Polyps in CT ColonographyHiroyuki Yoshida; Fiscal Year: 2010..abstract_text> ..
- GUANYLYL CYCLASE C AS A BI0MARKER FOR COLORECTAL CANCERScott Waldman; Fiscal Year: 2006....
- The Role of the APC Tumor Suppressor Gene in Hematopoiesis and LeukemogenesisZhijian Qian; Fiscal Year: 2010..In this proposal, we plan to determine how APC plays a role in the pathogenesis of MDS and t-MDS/t-AML, ultimately leading to new effective therapeutic strategies for these diseases. ..
- STAT1 Activation and HPP1 Tumor SuppressionDavid Shibata; Fiscal Year: 2010..is a recently identified gene that was initially discovered by virtue of its significant downregulation in colorectal neoplasms derived from patients with Hyperplastic Polyposis...
- Folate, 1-Carbon Nutrients, Gene Variants & Colon CancerDavid Hunter; Fiscal Year: 2007..studies that have examined the relationship between dietary folate intake and the risk of developing colorectal neoplasms, have reported that higher folate intakes are associated with lower risk...
- The biology of gastrin-ferric ion complexesGRAHAM BALDWIN; Fiscal Year: 2007..Recognition that metal ions are essential for the biological activity of NAGs may permit the development of novel therapies for colon cancer. ..
- The biology of gastrin-ferric ion complexesGRAHAM BALDWIN; Fiscal Year: 2009..Recognition that metal ions are essential for the biological activity of NAGs may permit the development of novel therapies for colon cancer. ..
- CHARACTERIZATION OF GENES FROM THE FAP LOCUSKENNETH KINZLER; Fiscal Year: 1993..The combination of the above studies should provide important insights into the role of APC and MCC in colorectal tumorigenesis...
- Emory-GA Tech Nanotechnology Center for Personalized an*Shuming Nie; Fiscal Year: 2007....